GenScript [HKEX:1548]
Connecting Gene Therapy from Discovery to Clinical Supply

GenScript [HKEX:1548] has built its gene-therapy platform around reducing that disruption. The company supports programs from target discovery through vector and payload development, then into phase-appropriate materials and clinical manufacturing support. Its capabilities span AAV and lentiviral systems alongside CRISPR reagents and mRNA-LNP technologies, giving developers multiple delivery options without losing sight of what later development and manufacturing will require.

The value lies less in the breadth of individual technologies than in the links between them across a program’s life cycle.

Design with the Next Stage in Mind

Gene-therapy development begins with a basic question. What biological change is worth pursuing?

GenScript supports that work through gene synthesis, sequencing, engineered cell models and CRISPR-based screening. These tools help researchers test and refine potential targets before committing to larger development resources. Once the biological rationale is established, the program moves from identifying the target toward designing the payload and choosing how it will reach the intended cells.

That payload and its delivery system have to be designed together. A sequence that performs well in one experimental setup may require optimization when packaged into an AAV vector or formulated as mRNA. GenScript supports expression cassette development and plasmid construction alongside viral-vector work and non-viral delivery technologies.

The development logic remains connected even when the delivery modality changes. A customer may be working with AAV for one program while another relies on synthetic guide RNA or an mRNA-LNP system. GenScript can support both approaches without requiring every program to follow the same delivery architecture.

Build Delivery Around the Therapy

AAV remains a major part of GenScript’s gene-therapy offering. The company supports plasmid preparation and vector packaging during research while providing a path toward more tightly controlled AAV development as the program advances.

The technical challenge is broader than producing viral particles. An AAV vector’s performance depends on several linked factors, including the design of the expression cassette, the behavior of its capsid and the ability of the manufacturer to reproduce the characteristics established during development. GenScript’s platform brings those activities closer together so the vector can be considered as part of the therapeutic design rather than as a delivery container chosen later.

Gene therapy now extends beyond a single delivery model. Some programs need the durability or tissue-targeting characteristics associated with viral vectors. Others benefit from transient expression or gene-editing approaches where non-viral delivery may be more appropriate.

GenScript’s role is to give developers a route through either path while keeping the surrounding development work connected.

The transition from research material toward clinical use is where continuity becomes especially valuable.

GenScript’s INDEdit gRNA offering was designed for programs approaching investigational new drug (IND)-enabling studies but not yet requiring full cGMP material. The product is manufactured within the company’s current good manufacturing practice (cGMP) facility, giving developers an intermediate step between research-grade reagents and later clinical-grade supply.

That approach addresses a practical development problem. Moving to a completely different production environment late in the program can trigger additional comparability work because investigators need confidence that the new material remains representative of the material used earlier.

GenScript provides guide RNA in grades suited to different development stages, allowing programs to increase manufacturing control as requirements rise instead of making an abrupt change in sourcing. The same development environment can also supply complementary components such as Cas proteins and DNA repair templates.

The model has moved beyond isolated research use. GenScript reported that its sgRNA capabilities had supported more than 50 regulatory filings and 22 global IND approvals as of the end of 2025. The significance is not simply the tally. It is the evidence that the platform meets regulatory expectations, rather than remaining confined to early research.

Carry the Vector into CMC and GMP

A successful research vector still has to become a reproducible clinical material.

GenScript connects that later-stage requirement through ProBio, its wholly owned contract development and manufacturing organization (CDMO) subsidiary. Within the wider gene-therapy platform, ProBio supports plasmid and viral-vector chemistry, manufacturing and controls (CMC) work alongside GMP controls, allowing programs to progress from development batches toward clinical supply.

The distinction between the companies is important. GenScript provides the broader life-science platform and early development capabilities, while ProBio contributes the specialized CDMO infrastructure required when a program reaches manufacturing-intensive stages.

Recent investment has strengthened that transition. ProBio expanded its GMP AAV capability and began supporting the AAV CMC program, while GenScript continued upgrading plasmid and viral-vector platforms. The company has reported AAV titers reaching 3 × 10¹² vector genomes per milliliter, with approximately 50 percent downstream recovery on its upgraded platform. In 2025, ProBio secured 60 cell and gene therapy CDMO projects, while GenScript reported new IND clearances across programs supported by the wider business.

The project count is less revealing than the continuity it creates. Customers can move from early genetic design to manufacturing support without turning each stage into a separate sourcing exercise.

Bring the Development Chain Closer to APAC

GenScript’s regional footprint gives that continuity additional relevance for APAC developers.

The company has operations across Singapore, Japan and Korea in addition to its extensive presence in China. Singapore is particularly important because GenScript has established local manufacturing for gene synthesis and recombinant protein services used across advanced life-science applications.

Its Singapore manufacturing facility covers approximately 3,500 square meters and supports premium gene synthesis together with gene-to-protein services. The site brings core research materials closer to customers, developing programs in the region and reducing reliance on distant production capacity.

GenScript also reported 33 percent year-over-year revenue growth in Asia-Pacific during 2025 while continuing to invest in manufacturing infrastructure across Singapore and mainland China.

Regional proximity does not replace the scientific or manufacturing challenge of gene therapy. A regional operating footprint can shorten the distance between developers and the technical resources they need as programs become more demanding.

GenScript’s recognition as a Top Gene Therapy Solutions provider in APAC reflects its focus on connecting stages that are often handled separately. A therapeutic concept may begin with a sequence and an experimental delivery method. Advancing it requires that the underlying development logic remain intact as materials become more tightly controlled and the program moves into CMC and GMP manufacturing.

GenScript is built to preserve that continuity. Its platform allows developers to design the payload and delivery strategy with later requirements already visible, and then increase the level of control around the material as the program moves toward the clinic.